239 related articles for article (PubMed ID: 34454293)
1. Anaphylatoxin receptor promiscuity for commonly used complement C5a peptide agonists.
Li XX; Clark RJ; Woodruff TM
Int Immunopharmacol; 2021 Nov; 100():108074. PubMed ID: 34454293
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Anaphylatoxin Receptor Expression and C3a/C5a Functions in Anaphylatoxin Receptor Reporter Mice.
Laumonnier Y; Karsten CM; Köhl G; Köhl J
Curr Protoc Immunol; 2020 Sep; 130(1):e100. PubMed ID: 32710701
[TBL] [Abstract][Full Text] [Related]
3. Development of Potent and Selective Agonists for Complement C5a Receptor 1 with In Vivo Activity.
Gorman DM; Li XX; Lee JD; Fung JN; Cui CS; Lee HS; Rolfe BE; Woodruff TM; Clark RJ
J Med Chem; 2021 Nov; 64(22):16598-16608. PubMed ID: 34762432
[TBL] [Abstract][Full Text] [Related]
4. Distinct roles of the anaphylatoxin receptors C3aR, C5aR1 and C5aR2 in experimental meningococcal infections.
Muenstermann M; Strobel L; Klos A; Wetsel RA; Woodruff TM; Köhl J; Johswich KO
Virulence; 2019 Dec; 10(1):677-694. PubMed ID: 31274379
[TBL] [Abstract][Full Text] [Related]
5. The "C3aR Antagonist" SB290157 is a Partial C5aR2 Agonist.
Li XX; Kumar V; Clark RJ; Lee JD; Woodruff TM
Front Pharmacol; 2020; 11():591398. PubMed ID: 33551801
[TBL] [Abstract][Full Text] [Related]
6. Partial ligand-receptor engagement yields functional bias at the human complement receptor, C5aR1.
Pandey S; Li XX; Srivastava A; Baidya M; Kumari P; Dwivedi H; Chaturvedi M; Ghosh E; Woodruff TM; Shukla AK
J Biol Chem; 2019 Jun; 294(24):9416-9429. PubMed ID: 31036565
[TBL] [Abstract][Full Text] [Related]
7. Discovery of functionally selective C5aR2 ligands: novel modulators of C5a signalling.
Croker DE; Monk PN; Halai R; Kaeslin G; Schofield Z; Wu MC; Clark RJ; Blaskovich MA; Morikis D; Floudas CA; Cooper MA; Woodruff TM
Immunol Cell Biol; 2016 Sep; 94(8):787-95. PubMed ID: 27108698
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterisation of small molecule C5aR1 inhibitors in human cells reveals biased activities for signalling and function.
Li XX; Lee JD; Massey NL; Guan C; Robertson AAB; Clark RJ; Woodruff TM
Biochem Pharmacol; 2020 Oct; 180():114156. PubMed ID: 32682759
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model.
Kollessery G; Nordgren TM; Mittal AK; Joshi SS; Sanderson SD
Vaccine; 2011 Aug; 29(35):5904-10. PubMed ID: 21723901
[TBL] [Abstract][Full Text] [Related]
10. Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity.
Finch AM; Vogen SM; Sherman SA; Kirnarsky L; Taylor SM; Sanderson SD
J Med Chem; 1997 Mar; 40(6):877-84. PubMed ID: 9083476
[TBL] [Abstract][Full Text] [Related]
11. Structure and characterization of a high affinity C5a monoclonal antibody that blocks binding to C5aR1 and C5aR2 receptors.
Colley CS; Popovic B; Sridharan S; Debreczeni JE; Hargeaves D; Fung M; An LL; Edwards B; Arnold J; England E; Eghobamien L; Sivars U; Flavell L; Renshaw J; Wickson K; Warrener P; Zha J; Bonnell J; Woods R; Wilkinson T; Dobson C; Vaughan TJ
MAbs; 2018 Jan; 10(1):104-117. PubMed ID: 28952876
[TBL] [Abstract][Full Text] [Related]
12. Distinct roles of the anaphylatoxins C3a and C5a in dendritic cell-mediated allergic asthma.
Engelke C; Wiese AV; Schmudde I; Ender F; Ströver HA; Vollbrandt T; König P; Laumonnier Y; Köhl J
J Immunol; 2014 Dec; 193(11):5387-401. PubMed ID: 25355927
[TBL] [Abstract][Full Text] [Related]
13. The influence of Lys68 in decepeptide agonists of C5a on C5a receptor binding, activation and selectivity.
Vogen SM; Finch AM; Wadi SK; Thatcher J; Monk PN; Taylor SM; Sanderson SD
J Pept Res; 1999 Jan; 53(1):8-17. PubMed ID: 10195437
[TBL] [Abstract][Full Text] [Related]
14. Role of complement anaphylatoxin receptors in a mouse model of acute burn-induced pain.
Morgan M; Deuis JR; Woodruff TM; Lewis RJ; Vetter I
Mol Immunol; 2018 Feb; 94():68-74. PubMed ID: 29274925
[TBL] [Abstract][Full Text] [Related]
15. Targeting C3a/C5a receptors inhibits human mesangial cell proliferation and alleviates immunoglobulin A nephropathy in mice.
Zhang Y; Yan X; Zhao T; Xu Q; Peng Q; Hu R; Quan S; Zhou Y; Xing G
Clin Exp Immunol; 2017 Jul; 189(1):60-70. PubMed ID: 28295247
[TBL] [Abstract][Full Text] [Related]
16. C5aR2 receptor: The genomic twin of the flamboyant C5aR1.
Das A; Gupta PK; Rana S
J Cell Biochem; 2022 Nov; 123(11):1841-1856. PubMed ID: 35977039
[TBL] [Abstract][Full Text] [Related]
17. New concepts on the therapeutic control of complement anaphylatoxin receptors.
Hawksworth OA; Li XX; Coulthard LG; Wolvetang EJ; Woodruff TM
Mol Immunol; 2017 Sep; 89():36-43. PubMed ID: 28576324
[TBL] [Abstract][Full Text] [Related]
18. Deficiency of Complement C3a and C5a receptors Does Not Prevent Angiotensin II-Induced Hypertension and Hypertensive End-Organ Damage.
Bode M; Herrnstadt GR; Dreher L; Ehnert N; Kirkerup P; Lindenmeyer MT; Meyer-Schwesinger CF; Ehmke H; Köhl J; Huber TB; Krebs CF; Steinmetz OM; Wiech T; Wenzel UO
Hypertension; 2024 Jan; 81(1):138-150. PubMed ID: 37909169
[TBL] [Abstract][Full Text] [Related]
19. TLQP-21 is a low potency partial C3aR activator on human primary macrophages.
Li XX; Lee JD; Lee HS; Clark RJ; Woodruff TM
Front Immunol; 2023; 14():1086673. PubMed ID: 36776827
[TBL] [Abstract][Full Text] [Related]
20. Response-selective C5a agonists: differential effects on neutropenia and hypotension in the rat.
Short AJ; Paczkowski NJ; Vogen SM; Sanderson SD; Taylor SM
Br J Pharmacol; 1999 Oct; 128(3):511-4. PubMed ID: 10516626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
